Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99.1 - VBI VACCINES INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: July 28, 2014
(Date of earliest event reported)
VBI VACCINES INC.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation) |
0-18188 (Commission File Number) |
93-0589534 (IRS Employer Identification Number) |
|
222 3rd Street, Suite 2241 Cambridge, Massachusetts (Address of principal executive offices) |
|
02142 (Zip Code) |
(617) 830-3031
(Registrant’s telephone number, including area code)
|
Paulson Capital (Delaware) Corp. 1331 NW Lovejoy Street, Suite 720 Portland, Oregon 97209 (Former Name or Former Address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On July 28, 2014, VBI Vaccines Inc., formerly known as Paulson Capital (Delaware) Corp. (the “Registrant”), issued a press release announcing the completion of the merger between the Registrant’s wholly owned subsidiary, VBI Acquisition Corp., a Delaware corporation, and Variation Biotechnologies (US), Inc., a Delaware corporation. A copy of the press release is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated July 28, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 28, 2014
|
|
VBI VACCINES INC. |
| |
| By: | /s/ Jeff Baxter | ||
|
|
|
Jeff Baxter |
|
|
|
|
Chief Executive Officer |
|
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated July 28, 2014 |